Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma

Clin Colorectal Cancer. 2022 Dec;21(4):371-374. doi: 10.1016/j.clcc.2022.08.001. Epub 2022 Aug 7.

Authors

Angelo Rizzolo¹, Kenny Chia Ah-Lan², Tuyet Nhung Ton Nu³, Thierry Alcindor⁴

Affiliations

¹ Department of Medicine, Cedars Cancer Center, McGill University Health Centre (MUHC), Montreal, QC, Canada.
² Department of Radiology, McGill University Health Centre (MUHC), Montreal, QC, Canada.
³ Department of Pathology, McGill University Health Centre (MUHC), Montreal, QC, Canada.
⁴ Department of Medicine, Cedars Cancer Center, McGill University Health Centre (MUHC), Montreal, QC, Canada. Electronic address: [email protected].

PMID: 36055919
DOI: 10.1016/j.clcc.2022.08.001

No abstract available

Keywords: Immunotherapy; Peritoneal mesothelioma.

Publication types

Case Reports

MeSH terms

Humans
Ipilimumab / adverse effects
Mesothelioma* / drug therapy
Mesothelioma* / pathology
Mesothelioma, Malignant*
Nivolumab / therapeutic use
Peritoneal Neoplasms* / drug therapy
Peritoneal Neoplasms* / pathology

Substances

Nivolumab
Ipilimumab